According to an SEC filing, Facebook Inc. (NASDAQ:FB) COO Sheryl Sandberg has sold a large amount of company stock, including $18 million on Thursday. Since February, Sandberg sold over $152 million worth of shares at prices that range between $58 per share to over $72. Facebook Inc. (NASDAQ:FB) net profit margin is 21.40% and weekly performance is -1.26%. On last trading day company shares ended up $62.50. Analysts mean target price for the company is $77.91. Facebook Inc. (NASDAQ:FB) distance from 50-day simple moving average (SMA50) is 3.90%.
SEC documents showed Adamis Pharmaceuticals Corp (NASDAQ:ADMP) Officer and Director David J. Marguglio sold 4,000 shares at $5.56 per share on Monday. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) shares advanced 1.51% in last trading session and ended the day on $5.38. ADMP return on assets is -259.60%.Adamis Pharmaceuticals Corp (NASDAQ:ADMP) quarterly performance is -14.33%.
pSivida Corp (NASDAQ:PSDV) announced its earnings results on 13 may, Tuesday. The company reported ($0.03) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.15) by $0.12, American Banking News reports. The company had revenue of $2.00 million for the quarter, compared to the consensus estimate of $0.55 million. pSivida Corp. (NASDAQ:PSDV) shares moved up 3.57% in last trading session and was closed at $3.77, while trading in range of $3.60 – $3.79. pSivida Corp. (NASDAQ:PSDV) year to date (YTD) performance is -5.04%.
At the 2014 Annual Meeting of Stockholders of Columbia Laboratories, Inc. (NASDAQ:CBRX), held on May 8, 2014, three proposals were submitted to and approved by the stockholders. The proposals are described in detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on March 31, 2014. Columbia Laboratories Inc. (NASDAQ:CBRX) ended the last trading day at $6.61. Company weekly volatility is calculated as 0.75% and price to cash ratio as 5.83.Columbia Laboratories Inc. (NASDAQ:CBRX) showed a negative weekly performance of -0.90%.
Acura Pharmaceuticals Inc. (NASDAQ:ACUR) was downgraded by analysts at TheStreet from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Tuesday. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) weekly performance is -1.89%. On last trading day company shares ended up $1.04. Analysts mean target price for the company is $1.75. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) distance from 50-day simple moving average (SMA50) is -19.17%.